Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

GT Biopharma (GTBP) Equity Average (2016 - 2021)

GT Biopharma (GTBP) has disclosed Equity Average for 8 consecutive years, with $34.1 million as the latest value for Q3 2021.

  • On a quarterly basis, Equity Average rose 219.01% to $34.1 million in Q3 2021 year-over-year; TTM through Sep 2021 was $34.1 million, a 219.01% increase, with the full-year FY2020 number at -$24.4 million, changed N/A from a year prior.
  • Equity Average was $34.1 million for Q3 2021 at GT Biopharma, up from $30.2 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $387.5 million in Q4 2017 to a low of -$29.6 million in Q4 2020.
  • A 5-year average of $104.2 million and a median of $30.2 million in 2021 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: surged 2560.47% in 2018, then tumbled 272.17% in 2020.
  • GT Biopharma's Equity Average stood at $387.5 million in 2017, then crashed by 66.53% to $129.7 million in 2018, then tumbled by 107.44% to -$9.6 million in 2019, then crashed by 207.03% to -$29.6 million in 2020, then soared by 215.13% to $34.1 million in 2021.
  • Per Business Quant, the three most recent readings for GTBP's Equity Average are $34.1 million (Q3 2021), $30.2 million (Q2 2021), and -$2.7 million (Q1 2021).